Services
Expertises
Resources
Who we are
Contact us
Open

Developing Medicines through Open Science (DMOS)

Supports open science drug development partnerships

Offered by
Conscience
Official source: conscience.ca

Source change captured

Funding available
$ 1,600,000
Up to 50% of project cost
Deadline
Unspecified
Location
Ontario, Canada
Who can apply
Canadian small and medium-sized enterprises (SMEs)
See full eligibility

Overview

The Developing Medicines through Open Science (DMOS) program provides up to $2,000,000 per project to support preclinical and clinical drug development in areas of unmet medical need. Eligible projects must involve at least one Canadian SME and align with Conscience’s open science approach.

At a glance

Funding available

Maximum funding
$1,600,000
Maximum share of project costs
50%
Financing goals
  • Develop strategic partnerships
  • Develop a new product or service
  • Conduct research and development activities
  • Conduct research or evaluation activities

Eligible candidates

Location
  • Ontario
Eligible Industries
All industries
Annual revenue
All revenue ranges
Organisation size
All organization sizes
Audience
  • Canadians
  • Startups
Legal structures
Non-profit, Public or Parapublic institution, For-profit business
Non-profit candidates
Sector of operation
Higher Education, Research, Other Health Services, Economic, Social and Community Development
Target groups
Business owners / entrepreneurs, Nonprofits / charities, Academia / students
Scope
National

Start applying for this program

Take a practical assessment to gain a clear understanding of how well this program aligns with your specific needs and long-term goals.

Availability timeline

2026
Periods: 1

Latest changes

DMSO added Québec collaborative call details

The page now includes a Québec-focused CQDM and Conscience collaborative call with new deadlines, eligibility rules, funding structure, and contact details.

See more

The grant page now includes a separate collaborative call for open science drug development for rare diseases, adding a Québec-focused opportunity with its own application deadlines and start date. It also introduces new eligibility requirements, including a Québec-based academic lead, a Québec SME partner, and project team and open data expectations specific to this call. Funding terms were also expanded to describe Québec-specific budget caps and contribution rules for research institutions and SMEs, along with new contact information for CQDM support. The original DMSO program information remains present, but the page now covers both the broader program and this targeted collaborative call.

Official source: conscience.ca
April 26, 2026

Eligibility

Who is eligible?

  • Canadian small and medium-sized enterprises (SMEs)
  • Academic research teams
  • Organizations involved in preclinical or clinical drug development

Eligible expenses

  • Project-related expenses that align with the approved research activities.
  • Travel expenses for attending project-progress events requested by the program.
  • Salaries and staff hours as tracked in submitted timesheets.
  • Other costs incurred with prior formal approval for changes to the research project.

Eligible geographic areas

  • Canadian companies

Activities funded

  • Preclinical and clinical drug development projects addressing unmet medical need.
  • Projects to develop drug candidates and establish proof of concept through open science.
  • Projects aiming for IND-enabling preclinical studies or human safety and efficacy studies.

How to apply

  • Step 1: Submit a one-page Letter of Intent through the online grants management portal.
  • Step 2: Wait for LOI review and feedback.
  • Step 3: If selected, submit the full proposal through the online grants management portal.
  • Step 4: If funded, sign the grant agreement and attend the virtual onboarding meeting.

Selection criteria

  • Scope fit and unmet medical need.
  • Scientific merit and feasibility of the approach.
  • Quality of the team and research environment.
  • Strength of the drug development plan.
  • Alignment with Conscience’s open science policy.

Processing and Agreement

  • LOIs are reviewed first, and selected applicants are invited to submit a full proposal.
  • Proposals are reviewed by a panel of scientific reviewers.
  • Applicants may receive feedback and be asked to make changes.
  • If approved, applicants must sign the grant agreement within the specified timeframe and attend a virtual onboarding meeting.

Additional information

  • Applications may be revised during review.
  • Conscience may request additional documents for audit purposes.
  • Selected applicants must sign a grant agreement and attend onboarding.

Official sources

Developing Medicines through Open Science (DMOS)

Program guide

Call for Collaborative Open Science Drug Development Projects for Orphan Diseases (2024)Frequently Asked Questions - Developing Medicines through Open Science (DMOS)Open Science Policy

Application form

Section 4 - Application Process
Add helloDarwin as a preferred source on Google

Frequently Asked Questions about the Developing Medicines through Open Science (DMOS) Program

What is the Developing Medicines through Open Science (DMOS)?

The Developing Medicines through Open Science (DMOS) program provides up to $2,000,000 per project to support preclinical and clinical drug development in areas of unmet medical need. Eligible projects must involve at least one Canadian SME and align with Conscience’s open science approach.

How much funding can be received?

Developing Medicines through Open Science (DMOS) Funds up to 50% of admissible expenses, capped at $1,600,000 per project.

What is the deadline to apply?

The program is accepting continuous intake

Who is eligible for the Developing Medicines through Open Science (DMOS) program?

To be eligible for the Developing Medicines through Open Science (DMOS) program, you must: Include at least one Canadian SME Research at TRLs 2-7 Matching funds required

What expenses are eligible under Developing Medicines through Open Science (DMOS)?

Project-related expenses that align with the approved research activities. Travel expenses for attending project-progress events requested by the program. Salaries and staff hours as tracked in submitted timesheets. Other costs incurred with prior formal approval for changes to the research project.

Where is the Developing Medicines through Open Science (DMOS) available?

The Developing Medicines through Open Science (DMOS) program is available the province of Ontario.

Is the Developing Medicines through Open Science (DMOS) a grant, loan, or tax credit?

Developing Medicines through Open Science (DMOS) is a Grant and Funding